[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on China's Hemocoagulase Market 2021-2025

July 2021 | 50 pages | ID: I6370060A1B7EN
China Research and Intelligence Co., Ltd.

US$ 2,600.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Hemocoagulase, developed by Swiss Sugo Pharmaceuticals, is a high-purity, single-component hemagglutinin clinical hemostatic drug. Its original drug is called REPTILASE, which is not on the market in China. In 2009, Hemocoagulase was firstly launched in China. Its product, Suling was developed by Beijing Kangchen Pharmaceutical Co., Ltd. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are 4 manufacturers in the Chinese Hemocoagulase market by 2020, among which Beijing Kangchen Pharmaceutical Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Hemocoagulase in the Chinese market is relatively stable from 2016 to 2019. In 2020, due to the impact of COVID-19 on the overall diagnosis and treatment services of the hospital, the sales value of Hemocoagulase in the Chinese market fell to CNY694 million in 2020, a year-on-year decline of 32%. The CAGR of Hemocoagulase sales value in the Chinese market from 2016 to 2020 is -11.05%.

CRI expects that with the relief of COVID-19, the sales value of Hemocoagulase in the Chinese market will have a restorative growth from 2021 to 2025. In addition, the Hemocoagulase injection is targeted, which cannot cause hypercoagulability in the blood. Based on this advantage, the sales value and sales volume of Hemocoagulase have a certain room for growth. At the same time, in the first half of 2021, China introduced a policy to encourage each couple to have three children. With the help of a new round of 'baby boom' that may come, China's procoagulant hemostatic drugs have a better market prospect, and sales value of Hemocoagulase are expected to be on the rise from 2021 to 2025.

Topics Covered:
  • The impact of COVID-19 on China's Hemocoagulase market
  • Sales value of China's Hemocoagulase 2016-2020
  • Competitive landscape of China's Hemocoagulase market
  • Prices of Hemocoagulase in China
  • Prices of Hemocoagulase in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Hemocoagulase market
  • Prospect of China's Hemocoagulase market from 2021 to 2025
1 RELEVANT CONCEPTS OF HEMOCOAGULASE

1.1 Indications for Hemocoagulase
1.2 Development of Hemocoagulase in China
1.3 Governmental Approval of Hemocoagulase in China
1.4 The Impact of COVID-19 on Hemocoagulase Sales in China

2 SALES OF HEMOCOAGULASE IN CHINA, 2016-2020

2.1 Sales Value of Hemocoagulase
  2.1.1 Overall Sales Value
  2.1.2 Sales Value by Region
2.2 Sales Volume of Hemocoagulase
  2.2.1 Overall Sales Volume
  2.2.2 Sales Volume by Region
2.3 Sales of Hemocoagulase by Dosage Form in China, 2016-2020
  2.3.1 Injection
  2.3.2 Analysis of Other Dosage Forms

3 ANALYSIS OF MAJOR HEMOCOAGULASE MANUFACTURERS IN CHINA, 2016-2020

3.1 Analysis of Market Share of Major Hemocoagulase Manufacturers
  3.1.1 Investigation on Market Share by Sales Value
  3.1.2 Investigation on Market Share by Sales volume
3.2 Beijing Kangchen Pharmaceutical Co., Ltd.
  3.2.1 Enterprise Profile
  3.2.2 Sales of Suling (Beijing Kangchen Pharmaceutical Co., Ltd. ’s Hemocoagulase) in China
3.3 Penglai Nuokang Pharmaceutical Co. Ltd.
  3.3.1 Enterprise Profile
  3.3.2 Sales of Kutai (Penglai Nuokang Pharmaceutical Co. Ltd.’s Hemocoagulase) in China
3.4 Jinzhou Aohong Pharmaceutical Co., Ltd.
  3.4.1 Enterprise Profile
  3.4.2 Sales of Bangting (Jinzhou Aohong Pharmaceutical Co., Ltd. ’s Hemocoagulase) in China
3.5 Zhaoke Pharmaceutical (Hefei) Co., Ltd.
  3.5.1 Enterprise Profile
  3.5.2 Sales of Sulejuan (Zhaoke Pharmaceutical (Hefei) Co., Ltd. ’s Hemocoagulase) in China

4 PRICES OF HEMOCOAGULASE FOR DIFFERENT MANUFACTURERS IN CHINA, 2020-2021

4.1 Beijing Kangchen Pharmaceutical Co., Ltd. (Suling)
4.2 Penglai Nuokang Pharmaceutical Co. Ltd. (Kutai)
4.3 Jinzhou Aohong Pharmaceutical Co., Ltd. (Bangting)
4.4 Zhaoke Pharmaceutical (Hefei) Co., Ltd. (Sulejuan)

5 PROSPECT OF CHINESE HEMOCOAGULASE DRUG MARKET, 2021-2025

5.1 Influential Factors of Chinese Hemocoagulase Market Development
  5.1.1 The Impact of COVID-19 on Chinese Hemocoagulase Market
  5.1.2 Market Drivers and Opportunities
  5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

LIST OF CHARTS

Chart Patent Information About Hemocoagulase Injection Registration in China
Chart Sales Value of Hemocoagulase Injection over the World
Chart Sales Value of Hemocoagulase Injection in China, 2016-2020
Chart Sales Value of Hemocoagulase Injection in China by Region, 2016-2020
Chart Sales Volume of Hemocoagulase Injection in China, 2016-2020
Chart Sales Volume of Hemocoagulase Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Hemocoagulase Manufacturers in China, 2016-2020
Chart Sales Value and Volume of Suling in China, 2016-2020
Chart Sales Value and Volume of Kutai in China, 2016-2020
Chart Sales Value and Volume of Bangting in China, 2016-2020
Chart Sales Value and Volume of Sulejuan in China, 2016-2020
Chart Referential Prices of Suling in China, 2020-2021
Chart Referential Prices of Kutai in China, 2020-2021
Chart Referential Prices of Bangting in China, 2020-2021
Chart Referential Prices of Sulejuan in China, 2020-2021
Chart Forecast on Sales Value of Hemocoagulase in China, 2021-2025
Chart Forecast on Sales Volume of Hemocoagulase in China, 2021-2025


More Publications